Evidence map›Paper›PMID 39993809›Full record

ArticleCancer genomics & proteomics

Engineered Methioninase-expressing Tumor-targeting

Yutaro Kubota, Ming Zhao, Qinghong Han, Yusuke Aoki, Noriyuki Masaki, Koya Obara, Sei Morinaga, Kohei Mizuta, Motokazu Sato, Michael Bouvet and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Methionine restriction and mimetics to ameliorate human aging and disease.Trends in endocrinology and metabolism: TEM · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yutaro KubotaAntiCancer Inc., San Diego, CA, U.S.A.
Ming ZhaoAntiCancer Inc., San Diego, CA, U.S.A.
Qinghong HanAntiCancer Inc., San Diego, CA, U.S.A.
Yusuke AokiAntiCancer Inc., San Diego, CA, U.S.A.
Noriyuki MasakiAntiCancer Inc., San Diego, CA, U.S.A.
Koya ObaraAntiCancer Inc., San Diego, CA, U.S.A.
Sei MorinagaAntiCancer Inc., San Diego, CA, U.S.A.
Kohei MizutaAntiCancer Inc., San Diego, CA, U.S.A.
Motokazu SatoAntiCancer Inc., San Diego, CA, U.S.A.
Michael BouvetDepartment of Surgery, University of California, San Diego, CA, U.S.A.
Koichi KubotaDepartment of Microbiology, Kitasato University School of Medicine, Kanagawa, Japan.
Takuya TsunodaDivision of Internal Medicine, Department of Medical Oncology, Showa University School of Medicine, Tokyo, Japan.
Robert M HoffmanAntiCancer Inc., San Diego, CA, U.S.A.; all@anticancer.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimWe previously developed MATERIALS AND

methodsA plasmid containing the

resultsThe mean LLC tumor size of each group on day 22 was as follows: PBS control: 741.5 mm

conclusionTumor-targeting

Indexed as

Carbon-Sulfur LyasesCarcinoma, Lewis LungMethionineSalmonella typhimuriumAnimalsDisease Models, AnimalMaleMiceMice, Inbred C57BLCarbon-Sulfur LyasesL-methionine gamma-lyaseMethionineC57BL/6 miceLewis lung carcinomamethioninase-producing Salmonella typhimurium A1-RSalmonella typhimurium A1-Rtumor inhibitiontumor methionine depletiontumor targeting

Identifiers

PMID39993809
PMCPMC11880925

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.